Biological activity and pathological implications of misfolded proteins

Cellular and Molecular Life Sciences

Volumn 55, Issue 6-7, 1999, Pages 977-991

  Bellotti, V ^a,b   Mangione, P ^a,b   Stoppini, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amyloidosis; Apolipoprotein AI; Lysozyme; Protein misfolding; Transthyretin; protein; 2 microglobulin

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; LYSOZYME; POLYMER; PREALBUMIN; PROTEIN;

AMYLOIDOSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033045668     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050348     Document Type: Review

References (112)

1. 1 Anfinsen C. B. (1973) Principles that govern the folding of protein chains. Science 181: 223-230
2. 2 Perutz M. F. (1997) Mutations make enzyme polymerize. Nature 385: 773-774
3. 3 Sunde M. and Blake C. C. F. (1998) From the globular to the fibrous state. Protein structure and structural conversion in amyloid formation. Quart. Rev. Biophys. 31: 1-39
4. 4 Pepys M. B., Hawkins P. N., Booth D. R., Vigushin D. M., Tennent G. A., Soutar A. K. et al. (1993) Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362: 553-557
5. 5 Booth D. R., Sunde M., Bellotti V., Robinson C. V., Hutchinson W. L., Fraser P. E. et al. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385: 787-793
6. 6 Strynadka N. C. J. and James M. N. G. (1991) Lysozyme revisited: crystallographic evidence for distortion of an N-acetylmuramic acid residue bound in site D. J. Mol. Biol. 220: 401-424
7. 7 Matagne A., Radford S. E. and Dobson C. M. (1997) Fast and slow tracks in lysozyme folding process. J. Mol. Biol. 267: 1068-1074
8. 8 Fersht A. (1984) In: Enzyme Structure and Mechanism, pp. 325-361, W. H. Freeman and Company (ed.), New York
9. 9 Segawa S. and Sugihara M. (1984) Characterization of the transition state of lysozyme unfolding. II. Effects of the intrachain crosslinking and the inhibitor binding on the transition state. Biopolymers 23: 2489-2498
10. 10 Bernard M., Canioni P., Cozzone P., Berthou J. and Jollès P. (1990) Effect of inhibitors on conformational changes in hen lysozyme around thermal transition point in solution and solid state. Int. J. Pept. Protein Res. 36: 46-55
11. 11 Hansen N. B., Karle H. and Andersen V. (1974) Production and elimination of plasma lysozyme. In: Lysozyme, pp. 307-319, Osserman E. F., Canfield R. E. and Beychok S. (eds). Academic Press, New York
12. 12 Park P. W., Biedermann K., Mecham L., Bissett D. L. and Mecham R. P. (1996) Lysozyme binds to elastin and protects elastin from elastase-mediated degradation. J. Invest. Dermatol. 106: 1075-1080
13. 13 Harrison R. F., Hawkins P. N., Roche W. R., MacMahon R. F., Hubscher S. G. and Buckels J. A. (1996) Fragile liver and massive hepatic haemorrhage due to hereditary amyloidosis. Gut 38: 151-152
14. 14 De la Paz P., Burridge J. M., Oatley S. J. and Blake C. C. F. (1992) Multiple modes of binding of thyroid hormones and other iodothyronines to human plasma transthyretin. In: The Design of Drugs to Macromolecular Targets, pp. 119-172, Beddell C. R. (ed.), Wiley, New York
15. 15 Weisner B. and Kauerz U. (1983) The influence of the choroid-plexus on the concentration of prealbumin in CSF. J. Neurol. Sci. 61: 27-35
16. 16 Monaco H. L., Rizzi M. and Coda A. (1995) Structure of a complex of two plasma proteins: transthyretin and retinol binding protein. Science 268: 1039-1041
17. 17 Blake C. C. F., Geisow M. J. and Oatley S. J. (1978) Structure of prealbumin (transthyretin): secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 121: 339-356
18. 18 Saraiva M. J. M. (1995) Transthyretin mutations in health and disease. Hum. Mutat. 5: 191-196
19. 19 Colon W. and Kelly J. W. (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31: 8654-8660
20. 20 Lai Z., Colon W. and Kelly J. W. (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 15: 6470-6482
21. 21 Kelly J. W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6: 11-17
22. 22 Lai Z., McCulloch J., Lashuel H. A. and Kelly J. W. (1997) Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry 36: 10230-10239
23. 23 Kelly J. W., Colon W., Lai Z., Lashuel H. A., McCulloch J., McCutchen S. L. et al. (1997) Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv. Protein Chem 50: 161-181
24. 24 Hermansen L. F., Bergman T., Jornval H., Husby G., Ranlov I. and Sletten K. (1995) Purification and characterisation of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy. Eur. J. Biochem. 227: 772-779
25. 25 Gustavsson A., Jahr H., Tobiassen R., Jacobson D. R., Sletten K. and Westermark P. (1995) Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab. Invest. 73: 703-708
26. 26 McCutchen S. L., Lai Z., Miroy G., Kelly J. W. and Colon W. (1995) Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34: 13527-13536
27. 27 Nettleton E. J., Sunde M., Lai Z., Kelly J. W., Dobson C. M. and Robinson C. V. (1998) Protein subunit interactions and structural integrity of amyloidogenic transthyretins: evidence from electrospray mass spectrometry. J. Mol. Biol. 281: 553-564
28. 28 Terry C. J., Damas A. M., Oliveira P., Saraiva M. J. M., Alves I. L., Costa P. P. et al. (1993) Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J. 12: 735-741
29. 29 Hamilton J. A., Steinrauf L. K., Braden B. C., Liepnieks J., Benson M. D., Holmgren G. et al. (1993) The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution. J. Biol. Chem. 268: 2416-2424
30. 30 Steinrauf L. K., Hamilton J. S., Braden B. C., Murrel J. R. and Benson M. D. (1993) X-ray crystal structure of the Ala 109 Thr variant of human transthyretin that produces euthyroid hyperthyroxinemia. J. Biol. Chem. 268: 2425-2430
31. 31 Saraiva M. J. M., Almeida M. R., Alves I. L., Bonifacio M. J., Damas A. M., Palha J. A. et al. (1996) Modulating conformalional factors in transthyretin amyloid. In: CIBA Symposium No. 199, The Nature and Origin of Amyloid Fibrils. pp. 47-57, Bock G. R. and Goode J. A. (eds), Wiley, Chichester
32. 32 Sebastiao M. P., Saraiva M. J. and Damas A. M. (1998) The crystal structure of amyloidogenic Leu 55-Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 273: 24715-24722
33. 33 Berni R., Malpeli G., Folli C., Murrell J. R., Liepnieks J. J. and Benson M. D. (1994) The Ile-84-Ser amino acid substitution in transthyretin interferes with the interaction with plasma Retinol-binding protein. J. Biol. Chem. 269: 23395-23398
34. 34 Vieira A. V., Sanders E. J. and Schneider W. J. (1995) Transport of serum transthyretin into chicken oocytes. J. Biol. Chem. 270: 2952-2956
35. 35 Sousa M. and Saraiva M. J. (1998) Characterization of receptor mediated internalization of transthyretin. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN. p. 95
36. 36 Miroy G. J., Lai Z., Lashuel H. A., Peterson S. A., Strang C. and Kelly J. (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93: 15051-15056
37. 37 Almeida M. R. and Saraiva M. J. (1996) Thyroxine binding to transthyretin (TTR) variants-two variants (TTR Pro 55 and TTR Met III) with a particular low binding affinity. Eur. J. Endocrinol. 135: 226-230
38. 38 Peterson S. A., Klabunde T., Lashuel H. A., Purkey H., Sacchettini J. C. and Kelly J. (1998) Inhibiting transthyretin conformational changes lead to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 95: 12956-12960
39. 39 Sjöhohm I. (1986) In: Drug Protein Binding. pp. 36-45, Reidenberg M. M. and Erill S. (eds), Praeger, New York
40. 40 Townsend A., Elliott T., Cerundolo V., Foster L., Barber B. and Tse A. (1990) Assembly of MHC class I molecules analyzed in vitro. Cell 62: 285-295
41. 41 Neefjes J., Hammerling G. and Momburg F. (1993) Folding and assembly of major histocompatibility complex class I heterodimers in the endoplasmic reticulum of intact cells precedes the binding of peptide. J. Exp. Med. 178: 1971-1980
42. 42 Machold R. P. and Ploegh H. L. (1996) Intermediates in the assembly and degradation of class I major histocompalibility complex (MHC) molecules probed with free heavy chain-specific monoclonal antibodies. J. Exp. Med. 184: 2251-2259
43. 43 Demaria S., Schawab R., Gottesman S. R. S. and Buskin Y. (1994) Soluble β2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J. Biol. Chem. 269: 6689-6694
44. 44 Pepys M. B. (1995) Amyloidosis. In: Oxford Textbook of Medicine, 3rd ed.. pp. 1512-1524, Weatherall D. J., Ledingham J. G. and Warrell D. A. (eds), Oxford University Press, Oxford
45. 45 Schwalbe S., Holzhauer M., Schaeffer J., Galanski M., Koch K. M. and Floege J. (1997) β2-microglobulin associated amyloidosis: A vanishing complication of long-term haemodialysis. Kidney Int. 52: 1077-1083
46. 46 Hakim R. M. (1993) Clinical implications of hemodialysis membrane biocompatibility. Kidney Int. 44: 484-494
47. 47 Zaoui P. M., Stone W. J. and Hakim R. M. (1980) Effects of membrane on beta-2 microglobulin production and cellular expression. Kidney Int. 38: 962-968
48. 48 Parker K. C., DiBrino M., Hull L. and Coligan J. E. (1992) The β2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J. Immunol. 149: 1896-1904
49. 49 Stoppini M., Bellotti V., Mangione P., Merlini G. and Ferri G. (1997) Use of anti-(β2 microglobulin) mAb to study formation of amyloid fibrils. Eur. J. Bioehem. 249: 21-29
50. 50 Yamazaki M., Asakura H., Saito M., Jokaji H., Uotani C., Kumabashiri I. et al. (1995) Relationship between elevation in the plasma concentration of elastase-alfa I proteinase inhibitor complex (E-alfa-Pi) and haemostatic parameters during haemodialysis. Blood Coagul. Fibrinolysis 6: 5-10
51. 51 Fremont D. H., Stura E. A., Matsumura M., Peterson P. A. and Wilson I. A. (1995) Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc. Natl. Acad. Sci. USA 92: 2479-2483
52. 52 Racchi M., Baetta K., Salvietti N., Ianna P., Franceschini G., Paolotti R. et al. (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 322: 893-898
53. 53 Homma N., Gejyo F., Isemura M. and Arakawa M. (1989) Collagen-binding affinity of beta-2-microglobulin, a preprotein of hemodialysis-associated amyloidosis. Nephron 53: 37-40
54. 54 Brinekerhoff C., Mitchel T. I., Karmilowicz M. J., Kluve Beckerman B. and Benson M. (1989) Autocrine induction of collagenase by serum amyloid A-like and beta2-microglobulin-like proteins. Science 243: 655-657
55. 55 Canalis E., McCarthy T. and Centrella M. (1987) A bone derived growth factor isolated from rat calvariae is beta 2 microglobulin. Endocrinology 121: 1198-1200
56. 56 Canalis E., McCarthy T. and Centrella M. (1988) Growth factors and the regulation of bone remodelling. J. Clin. Invest. 81: 277-281
57. 57 Connors L. H., Shirahama T., Skinner M., Fenves A. and Cohen A. S. (1985) In vitro formation of amyloid fibrils from intact beta 2-microglobulin. Biochem. Biophys. Res. Commun. 131: 1063-1068
58. 2-microglobulin amyloid fibrils in peripheral blood mononuclear cell culture. Am. J. Pathol. 141: 241-247
59. 59 Naiki H., Hashimoto N., Suzuky S., Kimura H., Nakakuki K. and Gejyo F. (1997) Establishment of a kinetic model of dialyis-related amyloid fibril extension in vitro. Amyloid: Int. J. Exp. Clin. Invest. 4: 223-232
60. 60 Bellotti V., Stoppini M., Mangione P., Sunde M., Robinson C., Asti L. et al. (1998) β2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. Eur. J. Biochem. 258: 61-67
61. 61 Isenman D. E., Painter R. H. and Dorrington H. J. (1975) The structure and function of immunoglobulin domains: studies with β2-microglobulin on the role of the intrachain disulfide bond. Proc. Natl. Acad. Sci. USA 72: 548-552
62. 62 Glomset J. A. (1968) The plasma lecithins:cholesterol acyl-transferase reaction. J. Lipid Res. 9: 155-167
63. 63 Ishida B. Y., Frolich J. and Fielding C. J. J. (1987) Pre-beta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. Lipid Res. 28: 778-786
64. 64 Borhani D. W., Rogers D. P., Engler J. A. and Brouillette C. G. (1997) Crystal structure of truncated human apolipoprotein A-1 suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA 94: 12291-12296
65. 65 Gursky O. and Atkinson D. (1996) Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular stale. Proc. Natl. Acad. Sci. USA 93: 2991-2995
66. 66 Nichols W. C., Dwulet F. E., Liepnieks J. and Benson M. D. (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem. Biophys. Res. Commun. 156: 762-768
67. 67 Nichols W. C., Gregg R. E., Brewer H. B. and Benson M. D. (1990) A mutation in apolipoprotein AI in the Iowa type of familial amyloidotic polyneuropathy. Genomics 8: 318-323
68. 68 Vigushin D. M., Gough J., Allan D., Alguacil A., Penner B., Pettigrevv N. M. et al. (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg 26. Q. J. Med. 87: 149-154
69. 69 Booth D. R., Tan S. Y., Booth S. E., Hsuan J. J., Totty N. F., Nguyen O. et al. (1995) A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Q. J. Med. 88: 695-702
70. 70 Soutar A. K., Hawkins P. N., Vigushin D. M., Tennent G. A., Booth S. E. and Hutton T. (1992) Apolipoprotein AI mutation Arg 60 causes autosomal dominant amyloidosis. Proc. Natl. Acad. Sci. USA 89: 7389-7393
71. 71 Persey M. R., Booth D. R., Booth S. E., Van Zyl-Smit R., Adam B. K., Fattaar A. B. et al. (1998) Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein AI. Kidney Int. 53: 276-281
72. 72 Booth D. R., Tan S. Y., Booth S. E., Tennent G. A., Hutchinson W. L., Hsuan J. J. et al. (1998) Hereditary hepatic and systemic amyloidosis caused by a novel variant apolipoprotein AI. Kidney Int. 53: 276-281
73. 73 Asl L. H., Liepnieks J. J., Asl K. H., Uemichi T., Moulin G., Desjoyaux E. et al. (1998) Hereditary cutaneous and cardiac amyloidosis caused by a new mutation in the apolipoprotein AI gene. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN, p. 96
74. 74 Tennent G. A., Booth D. R., Totty N. F., Sterlin A., Truong A., Booth S. E. et al. (1998) Hereditary systemic amyloid composed of normal apo-lipoprotein AI. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN, p. 97
75. 75 Westermark P., Mucchiano G., Marthin T., Johnson K. H. and Sletten K. (1995) Apolipoprotein AI-derived amyloid in human aortic atherosclerotic plaques. Am. J. Pathol. 147: 1186-1192
76. 76 Johnson K. H., Sletten K., Hayden D. W., O'Brien T. D., Roertgen K. E. and Westermark P. (1992) Pulmonary vascular amyloidosis in aged dogs: a new form of spontaneously occurring amyloidosis derived from apolipoprotein AI. Am. J. Pathol. 141: 1013-1019
77. 77 Roertgen K. E., Lund E. M., O'Brien T. D., Westermark P., Hayden D. W. and Johnson K. H. (1995) Apolipoprotein AI-derived pulmonary vascular amyloid in aged dogs. Am. J. Pathol. 147: 1311-1317
78. 78 Amarzguioui M., Mucchiano G., Haggqvist B., Westermark P., Kavlie A., Sletten K. et al. (1998) Extensive intimal apolipoprotein AI-derived amyloid deposits in a patient with an apolipoprotein AI mutation. Biochem. Biophys. Res. Commun. 242: 534-539
79. 79 Rogers D. P., Roberts L. M., Lebowitz J., Engler J. A. and Brouillette C. G. (1998) Structural analysis of apolipoprotein AI: effects of amino and carboxy-terminal deletions on the lipid-free structure. Biochemistry. 37: 945-955
80. 80 Rader D. J., Gregg R. E., Meng M. S., Schaefer J. R., Zech L. A., Benson M. D. et al. (1992) In vivo metabolism of a mutant apolipoprotein. apoA-Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J. Lipid Res. 33: 755-763
81. 81 Roma P., Gregg E., Meng M. S., Ronan R., Zech L. A., Franceschini G. et al. (1993) In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-I Milano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. 91: 1445-1452
82. 82 Genschel J., Haas R., Propsting M. J. and Schmidt H. H. J. (1998) Apolipoprotein A-I induced amyloidosis. FEBS Lett. 430: 145-149
83. 83 Pittman R. C. and Steiberg D. (1984) Sites and mechanisms of uptake and degradation of high density and low density lipoproteins. J. Lipid. Res. 25: 1577-1585
84. 84 Brownawell A. M. and Creutz C. E. (1996) Calcium dependent binding of the plasma protein Apolipoprotein A-I to two members of the annexin family. Biochemistry 35: 6839-6845
85. 85 Serpell L. C., Sunde M. and Blake C. C. F. (1997) The molecular basis of amyloidosis. Cell. Mol. Life Sci. 53: 871-887
86. 86 Pepys M. B., Booth D. R., Hutchinson W. L., Gallimore J. R., Collins P. M. and Hohenester E. (1997) Amyloid P component. A critical review. Amyloid: Int. J. Exp. Clin. Invest. 4: 274-295
87. 87 Magnus J. H. and Stenstad T. (1997) Protoglycans and the extracellular matrix in amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 4: 121-134
88. 88 Selkoe D. J. (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10: 373-403
89. 89 Teplow D. B. (1998) Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid: Int. J. Exp. Clin. Invest. 5: 121-142
90. 90 Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G. and Cotman C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13: 1676-1687
91. 91 Lorenzo A, and Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247
92. 92 Estus S., Tucker H. M., van Rooyen C., Wright S., Brigham E. F., Wogulis M. et al. (1997) Aggregated Amyloid-β protein induces cortical neuronal apoptosis and concomitant 'apoptotic' pattern of gene induction. J. Neuroscience 17: 7736-7745
93. 93 Anderson A. J., Cummings B. J. and Cotman C. W (1994) Increased immunoreactivity for Jun and Fos-related proteins in AD: association with pathology. Exp. Neurol. 125: 286-295
94. 94 Forloni G., Chiesa R., Smiroldo S., Verga L., Salmona M. and Tagliavini F. (1993) Apoptosis-mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. Neuroreport 4: 523-526
95. 95 Lindwall G. and Cole R. D. (1986) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259: 5301-5305
96. 96 Geula C., Wu C. K., Saroff D., Lorenzo A., Yuan M. and Yanker B. A. (1998) Aging renders the brain vulnerable to amyloid b-protein neurotoxicity. Nature Med. 4: 827-831
97. 97 Pepys M. B. (1996) Amyloid fibril toxicity. In: CIBA Symposium No. 199, The Nature and Origin of Amyloid Fibrils, pp. 44-45, Bock G. R. and Goode J. A. (eds), Wiley, Chichester
98. 98 Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R. and Liosatos M. (1998) Diffusible non fibrillar ligands derived from AβI 42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95: 6448-6453
99. 99 Yaar M., Zhai S., Pilch P. F., Doyle S. M., Eisenhauer P. B., Fine R. E. et al. (1997) Binding of β-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 100: 2333-2340
100. 100 Yan S. D., Chen X., Fu J., Chen M., Zhu H., Roher A. et al. (1996) RAGE and amyloid β peptide neurotoxicity in Alzheimer's disease. Nature 382: 716-719
101. 101 Wild-Bode C., Yamazaki T., Capell A., Leimer U., Steiner H., Ihara Y. et al. (1997) Intracellular generation and accumulation of Aβ terminating amino acid 42. J. Biol. Chem. 272: 16085-16088
102. 102 Yan S. D., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K. et al. (1997) An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389: 689-695
103. 103 Andersson K., Golsteins G. and Lundgren E. (1998) Transthyretin mutants exert cytotoxicity during amyloid formation. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN p. 94
104. 104 Lorenzo A., Razzaboni R., Weir G. D. and Yanker B. A. (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368: 756-760
105. 105 Janson J., Ashley R. and Butler P. (1998) Nascent human islet amyloid polypeptide is more cytotoxic and causes more membrane damage than mature fibrils. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN, p. 199
106. 106 Higham C. E., Badman M. K., Morris J. F. and Clark A. (1998) Fibriliar human islet amyloid polypeptide 'amylin' is cytotoxic to clonal cells and isolated B-cells but not to pancreatic islet in vitro. VIII International Symposium on Amyloidosis, Mayo Clinic, Rochester, MN, p. 220
107. 107 Lorenzo A. and Yankner B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247
108. 108 Merlini G., Ascari E., Amboldi N., Bellotti V., Arbustini E., Perfetti V. et al. (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils; inhibition of amyloidogenesis. Proc. Natl. Acad. Sci. USA 92: 2959-2963
109. 109 Tomiyama T., Kaneko H., Kataoka K., Asano S. and Endo N. (1997) Rifampicin inhibits the toxicity of pre-aggregated peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem. J. 322: 859-865
110. 110 Nicholls A., Sharp K. A. and Honig B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11: 281-296
111. 111 Saper M. A., Bjiorkman P. J. and Wiley D. C. (1991) Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J. Mol. Biol. 219: 277-319
112. 112 Bardin T., Bellini F. and Laredo J.D. (1989) Radiological evaluation of beta-2 microglobulin amyloidosis. In: Dialysis Amyloidosis, pp. 91-100, Gejyo F., Brancaccio D. and Bardin T. (eds), Wichting, Milano